RECURSION PHARMACEUTICALS, INC. Operating Leases, Rent Expense
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Operating Leases, Rent Expense of $6.40 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2024-02-29
- RECURSION PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2021-12-31 was $2.00M, a 300.00% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2021-09-30 was $1.70M, a 54.55% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2021-06-30 was $1.40M, a 27.27% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2021-03-31 was $1.30M, a 31.58% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2021 was $6.40M, a 72.97% increase from fiscal 2020.
- RECURSION PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2020 was $3.70M, a 0.00% change from fiscal 2019.
- RECURSION PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2019 was $3.70M.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.70M derived: sum of 2 quarters · filed 2024-02-29 | $5.10M derived: sum of 3 quarters · filed 2024-02-29 | $6.40M 10-K · filed 2024-02-29 |
| 2021-09-30 | $1.70M 10-Q · filed 2022-11-08 | $3.10M derived: sum of 2 quarters · filed 2022-11-08 | $4.40M 10-Q · filed 2022-11-08 | $4.90M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $1.40M 10-Q · filed 2022-08-09 | $2.70M 10-Q · filed 2022-08-09 | $3.20M derived: sum of 3 quarters · filed 2023-02-27 | $4.30M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.30M 10-Q · filed 2021-05-12 | $1.80M derived: sum of 2 quarters · filed 2023-02-27 | $2.90M derived: sum of 3 quarters · filed 2023-02-27 | $4.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.60M derived: sum of 2 quarters · filed 2023-02-27 | $2.70M derived: sum of 3 quarters · filed 2023-02-27 | $3.70M 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.10M 10-Q · filed 2021-11-10 | $2.20M derived: sum of 2 quarters · filed 2021-11-10 | $3.20M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $1.10M 10-Q · filed 2021-08-13 | $2.10M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $988.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $3.70M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |